Progenics On Way To The FDA With Second Product Offering Azedra
Executive Summary
Progenics looks set to expand its product portfolio with a mid-year filing expected for its novel radiopharmaceutical product in ultra-rare neuroendocrine tumors following success in a pivotal study conducted under an SPA.
You may also be interested in...
14 Approvals To Look Out For In Q3
As many as 14 new products are up for US approval in the third quarter, research by Informa Pharma's Biomedtracker shows. Scrip takes a look at the candidates and their chances of reaching the market.
Keeping Track: Ilumya, Adcetris Approved; Xtandi Priority Reviewed; Azedra Goal Date Extended
The latest drug development news and highlights from our US FDA Performance Tracker.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.